Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Lung cancer can co-opt genes that normally help a fetus develop and evade the mother's immune system. And while these ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic ...

Join us for a quick overview of BioNTech SE, a Biotechnology company whose shares moved 0.3% today. Here are some facts about ...

A healthy 36-year-old non-smoker from the UK, was misdiagnosed with anxiety for months before discovering he had terminal ...

Researchers from Guilin Medical University and collaborators investigated the potential role of ubiquitin-specific protease 4 (USP4) in the occurrence and development of lung adenocarcinoma.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

For example, recently, it has been shown that two checkpoint inhibitors (pembrolizumab and nivolumab) may increase the five-year survival of some patients with metastatic NSCLC ... Mcdermott R.

The trial (NCT04008030) enrolled immunotherapy-naïve patients with unresectable or metastatic MSI-H/dMMR CRC. The patients were randomly assigned to receive nivolumab plus ipilimumab, nivolumab ...

Autopsy demonstrated extensive metastatic carcinoma of the endometrium ... hematogenous spread throughout the lungs, obliterating lung structure in many areas. Comparison of the tumor at autopsy ...